U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly's oral drug, orforglipron, is still under review. Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.
The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk. It is the first pill of its kind to receive approval from the regulator, marking a new era for weight-loss drugs. Wegovy's Danish makers Novo Nordisk said the once-daily pill was a "convenient option" to the injectable and would provide the same weight loss as the shot.